HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

stenoparib

Poly(ADP-ribose) Polymerase (PARP) inhibitor

Also Known As:

8-(isoindolin-2-ylmethyl)-2,9-dihydro-3H-pyridazino(3,4,5-de)quinazolin-3-one; E-7449; E7449; PARP inhibitor 2X-121

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Azo Compounds: 333
  - stenoparib: 3
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Quinazolinones: 124
        stenoparib: 3
    - Isoquinolines: 34
      - stenoparib: 3

Experts

1.	McGonigle, Sharon: 2 articles (06/2018 - 12/2015)
2.	Nomoto, Kenichi: 2 articles (06/2018 - 12/2015)
3.	Wu, Jiayi: 2 articles (06/2018 - 12/2015)
4.	French, Christopher T: 1 article (01/2021)
5.	Jaramillo, Sierra A: 1 article (01/2021)
6.	Jones, Ashley N: 1 article (01/2021)
7.	Keim, Paul: 1 article (01/2021)
8.	Knudsen, Steen: 1 article (01/2021)
9.	Martz, Madison: 1 article (01/2021)
10.	Ng, Ken R: 1 article (01/2021)

Related Diseases

1.	Coronavirus Infections 01/01/2021 - "Moreover, our results suggest that stenoparib and remdesivir in combination may be especially potent against coronavirus infection."
2.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2021 - "The PARP inhibitor stenoparib may be such a drug, as it is currently in phase II clinical trials for the treatment of ovarian cancer and its safety and dosage in humans have already been established. " 01/01/2021 - "We evaluated a new poly(ADP-ribose) polymerase (PARP) inhibitor, stenoparib, that recently advanced to phase II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronaviruses, including SARS-CoV-2, in vitro Stenoparib exhibits dose-dependent suppression of SARS-CoV-2 multiplication and spread in Vero E6 monkey kidney and Calu-3 human lung adenocarcinoma cells. " 06/01/2018 - "Eribulin was combined with cytotoxic agents (capecitabine, carboplatin, cisplatin, doxorubicin, gemcitabine) or targeted agents (bevacizumab, BKM-120, E7449, erlotinib, everolimus, lenvatinib, palbociclib) in tumor xenograft models of breast cancer, melanoma, non-small cell lung cancer (NSCLC), and ovarian cancer. "
3.	Adenocarcinoma of Lung 01/01/2021 - "We evaluated a new poly(ADP-ribose) polymerase (PARP) inhibitor, stenoparib, that recently advanced to phase II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronaviruses, including SARS-CoV-2, in vitro Stenoparib exhibits dose-dependent suppression of SARS-CoV-2 multiplication and spread in Vero E6 monkey kidney and Calu-3 human lung adenocarcinoma cells. "
4.	Neoplasms (Cancer) 12/01/2015 - "E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling." 12/01/2015 - "E7449 represents a novel dual PARP1/2 and TNKS1/2 inhibitor which has the advantage of targeting Wnt/β-catenin signaling addicted tumors. " 12/01/2015 - "A pharmacodynamic effect of E7449 on Wnt target genes was observed in tumors, although E7449 lacked single agent antitumor activity in vivo, a finding typical for selective TNKS inhibitors. " 06/01/2018 - "Eribulin was combined with cytotoxic agents (capecitabine, carboplatin, cisplatin, doxorubicin, gemcitabine) or targeted agents (bevacizumab, BKM-120, E7449, erlotinib, everolimus, lenvatinib, palbociclib) in tumor xenograft models of breast cancer, melanoma, non-small cell lung cancer (NSCLC), and ovarian cancer. "
5.	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 12/01/2015 - "E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling."

Related Drugs and Biologics

1.	remdesivir
2.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
3.	Poly(ADP-ribose) Polymerase Inhibitors
4.	Catenins
5.	Carboplatin (JM8)
6.	Doxorubicin (Adriamycin)
7.	Cytotoxins (Cytolysins)
8.	Cisplatin (Platino)
9.	Antineoplastic Agents (Antineoplastics)
10.	Gemcitabine

Related Therapies and Procedures

1.	Therapeutics